Dear Editor,

We thank Yasri and Wiwanitkit for their comments on our work \[[@ref1]\]. In their response, they showed other factors that might alter the serum leptin level and this might be a limitation in using serum leptin as a clinical parameter in metabolic syndrome such in liver disease \[[@ref1]\]. Many factors may affect serum leptin levels such as physical activity, statin used and pharmacological intervention toward against renin-angiotensin system \[[@ref2]\]. In our study did not show significantly different of leptin levels between those treated or not with statins, fibrates, or antidiabetic drugs on peripheral arterial stiffness in patients with type 2 diabetes mellitus \[[@ref3]\]. Leptin is known to contribute to fibrogenesis in chronic liver diseases \[[@ref4]\]. However, studies on leptin levels and liver disease are controversial \[[@ref4]\]. Further studies are needed to confirm the liver disease on serum leptin levels in the future.
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